Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair’s Growth Stock Conference.
Robins said Adaptive, which was founded 16 years ago out of the Fred Hutch Center in Seattle and has been public since 2019, has more than 620 employees, about $277 million in revenue at the end of 2025 and a cash position of $220 million.
